Tumor Spreading to the Contralateral Ovary in Bilateral Ovarian Carcinoma Is a Late Event in Clonal Evolution by Micci, Francesca et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2010, Article ID 646340, 8 pages
doi:10.1155/2010/646340
Research Article
TumorSpreadingto theContralateral OvaryinBilateral Ovarian
Carcinoma Is a Late Event in Clonal Evolution
Francesca Micci,1 Lisbeth Haugom,1 Terje Ahlquist,2,3 Vera M. Abeler,4 Claes G. Trope,5
Ragnhild A. Lothe,2,3 andSverreHeim1,6
1Department of Medical Genetics, The Norwegian Radium Hospital, Oslo University Hospital, 0310 Oslo, Norway
2Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital,
Oslo University Hospital, 0310 Oslo, Norway
3Centre for Cancer Biomedicine, University of Oslo, 0310 Oslo, Norway
4Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, 0310 Oslo, Norway
5Department of Gynecology, The Norwegian Radium Hospital, Oslo University Hospital, 0310 Oslo, Norway
6Faculty of Medicine, University of Oslo, 0310 Oslo, Norway
Correspondence should be addressed to Francesca Micci, francesca.micci@labmed.uio.no
Received 25 May 2009; Accepted 25 June 2009
Academic Editor: Ben Davidson
Copyright © 2010 Francesca Micci et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Cancer of the ovary is bilateral in 25%. Cytogenetic analysis could determine whether the disease in bilateral cases is metastatic
or two separately occurring primary tumors, but karyotypic information comparing the two cancerous ovaries is limited to a
single report with 11 informative cases. We present a series of 32 bilateral ovarian carcinoma cases, analyzed by karyotyping and
high-resolution CGH. Our karyotypic ﬁndings showed that spreading to the contralateral ovary had occurred in bilateral ovarian
cancer cases and that it was a late event in the clonal evolution of the tumors. This was conﬁrmed by the large number of similar
changes detected by HR-CGH in the diﬀerent lesions from the same patient. The chromosomal bands most frequently involved
in structural rearrangements were 19p13 (n = 12) and 19q13 (n = 11). The chromosomal bands most frequently gained by
both tumorous ovaries were 5p14 (70%), 8q23-24 (65%), 1q23-24 (57%), and 12p12 (48%), whereas the most frequently lost
bands were 17p11 (78%), 17p13 (74%), 17p12 (70%), 22q13 (61%), 8p21 and 19q13 (52%), and 8p22-23 (48%). This is the ﬁrst
time that 5p14 is seen gained at such a high frequency in cancer of the ovary; possibly oncogene(s) involved in bilateral ovarian
carcinogenesis or tumor progression may reside in this band.
1.Introduction
Cancer of the ovary represents 30% of all malignancies of
the female genital organs [1]. The most common ovarian
neoplasms,typicallyoccurringinwomenofreproductiveage
and beyond, originate from the ovarian surface epithelium
and belong to one of three major types: serous, mucinous,
and endometrioid tumors. These neoplasms range from the
clearly benign (80%) to highly malignant carcinomas, with
tumors of borderline malignancy in between.
Bilateral carcinomas of the ovary vary in frequency
depending on which tumor type is involved but can be
found in roughly 25% of all ovarian cancer cases [2].
The question of whether bilateral ovarian carcinomas are
the result of metastatic spreading from one ovary har-
boring the primary tumor to the contralateral ovary, as
opposed to the alternative, simultaneous occurrence of
two independent primary tumors, was addressed nearly
t w od e c a d e sa g ob yP e j o v i ce ta l .[ 3]. In a chromosome
banding analysis they found no clear-cut diﬀerence in
the karyotypic pattern between the tumors of the two
ovaries in each woman but considerable diﬀerences from
case to case. Hence, metastatic spreading from one side
to the other must have been the pathogenetic mechanism,
although the side carrying the primary tumor could not be
identiﬁed. No similar later studies have been undertaken
to conﬁrm or falsify the ﬁndings and conclusions then
made.2 Journal of Oncology
We present a series of 32 bilateral ovarian carcinoma
cases, in six also including cancerous lesions in the omentum
or peritoneum, analyzed primarily by karyotyping and
high-resolution comparative genomic hybridization (HR-
CGH) but also tested for microsatellite instability. Because
the ﬁndings in the two or three samples from each woman
werelargelysimilar,weconcludethatbilateralovariancancer
occurs by a metastatic process and that spreading to the
contralateral ovary mostly is a late event in the clonal
evolution of these cancers.
2.MaterialsandMethods
2.1. Tumors. The examined material consists of 70 fresh
samples from ovarian carcinomas surgically removed at
The Norwegian Radium Hospital from 1999 to 2004 (see
Table 1 in Supplementary Material available online at
doi:10.1155/2010/646340). The tumors were part of a con-
secutive series of 248 ovarian tumors cultured and kary-
otyped by us (of which 203 were carcinomas; unpublished
data). The 70 tumors came from altogether 32 patients with
bilateral ovarian cancer. From all patients we had tumor
materialfrombothovaries,andfromsixpatientswealsohad
samples from a metastasis to the omentum (three patients)
or peritoneal cavity (three patients). Neoadjuvant therapy
had been given to four patients before surgery (cases 5,
9, 22, and 24); otherwise, no preoperative chemotherapy
or irradiation had been given. The tumors were classiﬁed
as serous papillary adenocarcinoma (22 cases; Supplemen-
tary Table 1), endometrioid carcinoma (cases 23, 29, and
31), adenocarcinoma NOS (case 24), carcinosarcoma (case
21), and mucinous adenocarcinoma (case 26), and four
cases showed a mixed histology and were classiﬁed as
endometrioid and serous papillary (cases 3, 6, and 27)
and clear cell and serous papillary carcinoma (case 28).
The tumors also showed diﬀerent patterns of diﬀerentiation
(well, moderately, and poorly diﬀerentiated; Supplementary
Table 1).
2.2.CellCulturingandKaryotyping. Thetumorsampleswere
manually minced and disaggregated with Collagen II (Wor-
thington, Freehold, NJ, USA) until a suitable suspension
of cells and cell clumps was obtained. After 6-7 days of
culturing in a selective medium [4], colchicine was added
and the cultures harvested according to Mandahl [5]. The
chromosomesofthedividingcellswerethenG-bandedanda
karyotype established according to the recommendations of
the ISCN [6].
2.3. High-Resolution Comparative Genomic Hybridization
(HR-CGH). DNA was isolated by the phenol-chloroform
method as previously described [7]. CGH [8]w a sp e r f o rm e d
according to our modiﬁcations of standard procedures [9].
Chromosomes were karyotyped based on their inverted
DAPI appearance and the relative hybridization signal inten-
sity was determined along each chromosome. An average of
1 0 – 1 5m e t a p h a s e sw a sa n a l y z e d .An e g a t i v e( n o r m a lv e r s u s
normal) and a positive (a cell line with known copy number
changes) controls were included in the experiments. For the
scoring of CGH results, we adopted the use of dynamic
standard reference intervals (D-SRI). A D-SRI represents a
“normal” ratio proﬁle that takes into account the amount of
v a r i a t i o nd e t e c t e di nn e g a t i v ec o n t r o l sf o re a c hc h r o m o s o m e
band. This provides a more objective and sensitive scoring
criterion than ﬁxed thresholds [10–12] and, consequently, a
higher resolution. The D-SRI used was generated with data
from 10 normal versus normal hybridizations (totalling 110
cells). This interval was automatically scaled onto each sam-
ple proﬁle, and aberrations were scored whenever the case
proﬁle and the standard reference proﬁle at 99% conﬁdence
intervals did not overlap. The description of the CGH copy
number changes was based on the recommendation of the
ISCN [6].
2.4. Microsatellite Instability Status. The tumor’s microsatel-
lite instability (MSI) status was determined in all samples
using a consensus panel of ﬁve microsatellite markers
(BAT25, BAT26, D2S123, D5S346, and D17S250) [13]. A
tumor was considered to be MSI-high if two or more of
the ﬁve markers exhibited novel alleles compared to normal
DNA, MSI-low if only one marker deviated from the normal
pattern, and microsatellite stable (MSS) if none of the tumor
genotypes showed an aberrant pattern. Control DNA corre-
sponding to the individual tumors was not available from
the patients and therefore single allele changes, that is, the
presence of two diﬀerent alleles, can reﬂect a heterozygous
constitutional genotype or a homozygous genotype with a
novel tumor-speciﬁc allele. Thus, dinucleotide markers were
not scored when such a pattern appeared in the tumors.
The MSI status was assessed according to Wu et al. [14].
AllelicsizesweredeterminedusingGeneMapper3.7software
(Applied Biosystems, Foster City, CA, USA), and the results
were independently scored by two investigators. A second
round of analyses was always performed, conﬁrming the
ﬁndings.
3. Results
The cell culturing and subsequent G-banding cytogenetic
analysis gave informative results in 58 samples (Supplemen-
tary Table 1), 39 of which showed an abnormal karyotype
whereas 19 were normal. The remaining 12 samples were
culture failures and therefore could not be examined using
this technique. The abnormal karyotypes were complex;
that is, more than four abnormalities were present in all
informative cases but one, case 21. This case was the only
carcinosarcoma of our series; the tumor of the right ovary
(case 21b) showed a der(16)t(1;16)(q21;q22) as the sole
abnormality whereas a complex karyotype was seen in the
tumor of the left ovary (case 21a), but with a similar
der(16)t(1;16)(q21;q22) as one of many changes. Mostly
many more aberrations than four were seen, several of which
could not be completely identiﬁed. The modal chromosome
number was hypodiploid in six cases, diploid in three,
hyperdiploidinthree,hypotriploidinonecase,hypertriploid
in 19, neartetraploid in one, hyperpentaploid in three cases,Journal of Oncology 3
and a mix of hyperdiploid and hypertetraploid clones in one
(case 5a). For 14 cases, we obtained abnormal karyotypes
from either both ovaries or from one ovarian tumor and
a metastasis in the omentum/peritoneum, but in six of these
cases, the technical quality was not suﬃciently good to be
able to compare the karyotypic data from diﬀerent lesions
in a reliable way. For eight patients, however, it was possible
to compare the abnormal karyotypes, and in one additional
patient both ovarian tumors and the peritoneal metastasis
yielded informative results and could be compared (cases 8a,
8b, and 8c in Supplementary Table 1). In all these nine cases,
more or less extensive karyotypic similarities between the
samples taken from the diﬀerent tumor lesions were found,
with the number of identical aberrations ranging from one
to eight per karyotype. However, because in seven out of
these nine cases the karyotypic description was incomplete
due to the complexity of the rearrangements, it is possible
that more common abnormalities were present. In cases 19a
and 19b, the karyotypic description was identical for the two
tumorous ovaries (Figure 1).
The chromosomes seen to be most frequently involved
in structural rearrangements by G-banding analysis were,
in order of falling frequency, chromosomes 19, 1, 11, and
16 (Figure 2). The bands most frequently rearranged were
19p13(involvedin12rearrangements),19q13(11rearrange-
ments), 1q21, 16q22, and 19q10-11 (six rearrangements),
11p15, 12p13, and 15p11 (ﬁve rearrangements each), and
1p36 and 16q24 (four rearrangements each). The chromo-
somes most frequently involved in numerical aberrations
weretheXchromosome(ineighttumors)andchromosomes
8 and 14, involved in six tumors each.
The HR-CGH gave informative results on 60 samples
showing genomic imbalances in 56 of them. From seven
lesions there was no DNA available for analysis. No informa-
tive results were obtained in cases 13b, 22b, and 32b because
of poor quality of the hybridization signal, despite running
the experiments twice. In six cases, the G-banding karyotype
matched the imbalances detected by CGH well. However,
because the G-banding analysis often showed an incomplete
karyotype with marker chromosomes and additional mate-
rial of unknown origin sitting on known chromosomes, the
CGH analysis allowed the identiﬁcation of more imbalances.
In 17 cases, a normal karyotype was detected by G-banding
analysis whereas the CGH experiments showed genomic
imbalances in the tumor samples. We gained information
also on the 10 cases that were culture failures, ﬁnding
imbalances in seven of them. Gains were more frequent
than losses as seen by HR-CGH, and high-level ampliﬁcation
was found in 23 lesions. The major copy number changes
were gains of or from chromosome arms 1p, 1q, 2p, 3q,
5p, 8q, 11q, 12p, and 20q and losses of or from Xp, 4q,
5q, 6q, 8p, 13q, 16q, 17p, 17q, 18q, 19q, and 22q. More
speciﬁcally, the most frequently gained bands were, in order
of decreasing frequency, 5p14 and 8q23 (39%), 2p23 (38%),
1q24, 3q25, and 3q27q28 (36%), 1q21, and 3q22 (34%),
2p13, 3q13, and 8q21 (32%), 1p31 (30%), 20q13 (29%), and
11q22 and 12p12 (25%). The most frequently lost bands
were 17p11 and 17p13 (45%), 17p12 (43%), 16q23 and
22q13 (38%), 8p21 and 17q21 (34%), 8p22-23 (32%), Xp21
and 6q25 (30%), 4q34, and 18q22 (29%), 13q14 and 19q13
(27%), and 5q13-14 (25%) (Figure 3(a)). A comparison of
the imbalances scored for the tumors in the two ovaries
and/or the omentum/peritoneum showed that the bands
most often gained by both ovarian tumors were 5p14 (70%
of the 23 cases or 46 samples showing informative results),
8q23-24 (65%), 1q23-24 (57%), 12p12 (48%), 2q23 and
3q22 (43%), and 2p23, 3q13-21, 3q24-28, and 11q14 (39%).
The most often lost bands were 17p11 (78%), 17p13 (74%),
17p12 (70%), 22q13 (61%), 8p21 and 19q13 (52%), 8p22-
23 (48%), 16q22-23, 17q12-21, and 18q22 (43%), and 4q31,
4q33q34, 11p15, and Xp21 (39% each; Figure 3(b)).
The samples showed from one (samples 4a and 4b) to
58 (sample 11a) copy number alterations with an average
number of copy alterations (ANCA) index of 37.9. Ampli-
ﬁcations were most often scored on chromosome arms 8q
(eight tumors) and 3q and 12p (four tumors each).
As ovarian cancer can be part of the hereditary non-
polyposis colon cancer (HNPCC) spectrum, characterized
by microsatellite instability (MSI); we tested for this in the
present series. Fifty-nine tumors gave informative results.
Fifty-six of the tumors were classiﬁed as microsatellite stable
(MSS) as none of the tumor genotypes showed an aberrant
pattern; these were MSS tumors. Three cases (9a, 9c, and
16b) were scored as MSI-low (MSI-L; Supplementary Table
1). In four cases, the MSI status could not be determined in
spite of running the experiments twice. The remaining seven
samples were not analyzed as there was no DNA available.
4. Discussion
Cytogenetic studies of bilateral ovarian cancer are limited to
the one by Pejovic et al. [3]w h ok a r y o t y p e dt u m o r sf r o m
both ovaries in 15 patients. Because the baseline karyotypes
in each tumor pair were identical in the 11 patients from
whom informative results were obtained, the conclusion
was that the second tumor always arose by spreading of a
monoclonal process from the ﬁrst one. However, since the
clonal evolution of the neoplastic cells in the two locations
was similar, one could not determine which tumor was
primary and which was metastatic.
We report a series of 32 patients with bilateral ovar-
ian cancer analyzed by karyotyping, HR-CGH, and a
microsatellite instability assay. As in the study by Pejovic
et al. [3], considerable similarity was observed between
the left-sided and right-sided tumors. From one to eight
common aberrations were seen by karyotyping in the
nine patients from whom informative results for both
ovaries/omentum/peritoneum were obtained, averaging 3.22
common aberrations per patient. Because the karyotypic
descriptions were incomplete, more common aberrations
may have remained hidden among the markers. Indeed, the
HR-CGH analysis revealed from one (cases 4 and 31) to
43 (case 1) genomic imbalances common to both or all
lesions in the 23 patients from whom informative results for
bothovaries/omentum/peritoneumwereobtained,givingan
average of 25.5 common aberrations per case or patient.
Our ﬁndings therefore conﬁrm the conclusions of Pejovic et4 Journal of Oncology
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Figure 1: Tumor karyotypes from case 19. The two cancerous ovaries showed an identical karyotype with two related clones: (a)
54,XX,+X,+5,+8,+8,+12,+14,+14,+16, and (b) 52,XX,+X,+5,+8,+8,inv(10)(p12q22),+12,+der(16)t(14;16)(q13;q22),del(17)(p12). Arrows
point to numerical changes, arrowheads to structural rearrangements.
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Figure 2: Breakpoint positions (circles to the right) and numerical changes (lines; losses to the left and gains to the right) detected in the
chromosome aberrations of 32 cases of bilateral ovarian cancer.
al. [3] that bilateral ovarian cancer occurs via a metastatic
mechanism, but the addition of CGH data allowed us to
expand on this assessment of the pathogenetic connection
between macroscopically discrete tumor lesions: the fact that
so many aberrations are common to the tumors in both sides
indicates that spreading to the contralateral ovary is a late
event in the clonal evolution of the neoplastic parenchyma
cells. The aberrations unique to each tumor lesion, on the
other hand, in all likelihood arose after the metastasis was set
up, in the other-sided ovary or in the omentum/peritoneum.
The data are too sparse to conclude with certainty whether
the latter metastases diﬀer in any signiﬁcant way from the
tumors situated in the ovaries themselves when it comes to
acquired genomic aberrations, but this does not appear to be
the case.
In the present study, the chromosomes most frequently
involved in numerical aberrations were the X chromo-
some and chromosomes 8 and 14. More precisely, the X
chromosome was lost in six tumors and gained in two,
whereas chromosomes 8 and 14 were involved in numerical
aberrations in six tumors each, equally often in gains
and losses. These numerical aberrations are well known
in ovarian carcinomas [15]. The mechanisms behind their
occurrence are unknown as are their pathogenetic eﬀects.Journal of Oncology 5
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Figure3:(a)AllgenomicimbalancesdetectedbyHR-CGHin56tumorlesionsfromaltogether32casesofbilateralovariancancer(including
six metastases to the omentum/peritoneum). (b) Genomic imbalances detected by HR-CGH in both tumorous ovaries from the 23 cases
yielding informative results. The data from the latter subset are likely to reﬂect the earliest genomic changes, since they are present in both
tumor lesions. Some of the imbalances in the former and larger group may have been acquired after spreading, since they also include
ﬁndings in only one tumor per case.
The chromosome most frequently involved in structural
rearrangements was chromosome 19; more speciﬁcally,
19p13 was involved in 12 rearrangements in eight tumors,
whereas 19q13 was involved in 11 rearrangements in eight
tumors, and the centromeric region of chromosome 19 was
involved in six rearrangements in three cases. Alterations of
19p13 particularly, but also 19q13, in the form of added
extra material are known to be among the most frequent
cytogenetic aberrations in ovarian carcinomas [4, 16–18].
Sometimes the 19p+ or 19q+ markers look alike [16, 19],
but the origin of the additional material could only rarely
be identiﬁed [4]. The rearrangements of chromosome 19
have never been seen as the only chromosomal aberration
in ovarian carcinoma, and so it seems likely that they
are progressional rather than primary anomalies. Their
detection here in many cases indicates that they show no
frequency-diﬀerencebetweenunilateralandbilateralovarian
carcinomas.
Rearrangements of chromosome 1 were also detected
quite often in the present series, involving mostly 1q21 (six
rearrangements) and 1p36 (four rearrangements). Similar
aberrations were also previously reported. Pejovic et al. [16,
19] found frequent deletions of the distal half of 1q and
various abnormalities resulting in loss of 1p34-36. Again, no
diﬀerence between the current series of bilateral carcinomas
and ovarian carcinomas in general is discernible.
Another hot-spot of chromosomal rearrangements in
our series was 11p14-15 (eight rearrangements in total,
ﬁve mapped to 11p15 and three to 11p14). Often the
rearrangements are described as an add(11)(p14-15) which,
in addition to the added material, may well also lead
to loss of 11p-material distal to the breakpoint. Similar
changes have been reported by other investigators [16,
20, 21]. Also chromosomal bands 16q22 and 16q24 were
repeatedly rearranged in the present series, in six and four
cases, respectively. The Mitelman database of chromosome
aberrations in cancer reports such changes in ﬁve and
14 ovarian carcinomas, respectively [22]. As for the other
above-mentioned changes, neither the genes involved nor
anything else about the mechanism of their contribution to
tumorigenesis is known.
The karyotypic features of the only bilateral carci-
nosarcoma analyzed in the present series deserve special
mention. The tumor of the left ovary showed two apparently
unrelated clones with many abnormalities in an incom-
plete karyotypic description. The right-sided tumor had a
46,XX,der(16)t(1;16)(q21;q22) as the sole abnormality in all
analyzed cells, an aberration that was shared also by the
contralateral tumor. In contrast to what appears to be the
general rule in the other bilateral tumors, therefore, spread-
ing to the left side seems to have taken place early in clonal
evolution in this case. Unfortunately, no DNA was available
to perform CGH on the tumor from the right side of this
case to compare the genomic imbalances of the two lesions.
Carcinosarcomas or malignant mixed mesodermal tumors
comprise less than 1% of ovarian neoplasms [23]. They
are microscopically characterized by a mixture of malignant
epithelial and stromal element, similar to what is observed
in corresponding uterine tumors [23]. There are altogether
ten such tumors reported with karyotypic aberrations [24–
30]. Rearrangement of chromosome 1 seems to be the most
frequent cytogenetic change in carcinosarcomas of the ovary
as well as of the uterus [9].
The bands most often seen by HR-CGH to be gained
in both tumorous ovaries were 5p14 (70% of the 23 cases
or 46 samples), 8q23-24 (65%), 1q23-24 (57%), 12p126 Journal of Oncology
(48%), 2q23 and 3q22 (43%), and 2p23, 3q13-21, 3q24-
28, and 11q14 (39%). The most often lost bands were
17p11 (78%), 17p13 (74%), 17p12 (70%), 22q13 (61%),
8p21 and 19q13 (52%), 16q22-23, 17q12-21, and 18q22
(43%), and 4q31, 4q33-34, 11p15, and Xp21 (39%). This
picture of imbalances by and large tallies well with what has
been reported before in unilateral ovarian carcinomas. The
most common imbalances detected in ovarian carcinomas
by chromosome-based CGH have been gains of or from
chromosome arms 1q, 3q, 8q, 12p, and 20q and losses of or
from 4p, 4q, 8p, 13q, 16q, 18q, and Xp [31–39]. Interestingly,
the chromosomal band most frequently gained in our series
of bilateral ovarian carcinomas was 5p14, being gained in
70% of the cases. This is the ﬁrst time that the short arm
of chromosome 5 is seen to be gained so often in ovarian
carcinomas. The two only previous reports in which the
same band was found gained showed a frequency of 17.6%
(three out of 17 sampled analyzed; [40]) and 41.1% (six
out of 13 samples analyzed; [41]). In addition, a CGH
proﬁle of 543 cases of ovarian carcinomas (summarized
in http://www.progenetix.net/) shows a proﬁle for 5p14
with 14.4% gains, 3.9% losses, and 1.3% ampliﬁcations.
An explanation for the higher frequency of gain of 5p14
observed in our series could be found in the fact that
our data are based on high-resolution CGH, a method
that is known to be more sensitive in the detection of
imbalances compared to normal chromosomal CGH [12].
The most exciting possibility, of course, would be that the
observed gain has to do with a tumor’s propensity to spread
to the contralateral side, but conﬁrmation in independent
studies is needed before we ascribe much credibility to
this explanation. Regardless of what it might mean, the
direct pathogenetic signiﬁcance of this speciﬁc gain remains
unknown; possibly oncogene(s) located in 5p14 may be
active in ovarian carcinogenesis and/or tumor progression
and spreading.
The most frequent losses seen in the present series were
from 17p, more precisely 17p11 in 78% of the samples,
17p13 in 74%, and 17p12 in 70%. Much interest has focused
on the loss of genetic information from the short arm of
chromosome 17, where losses seem to occur especially at
17p13.1 [42, 43]a sw e l la sa ta ne v e nm o r ed i s t a ll o c u si n
17p13.3[42,44].Twopossibletargettumorsuppressorgenes
have been mapped to 17p13.3, OVCA1 and OVCA2 [45].
The target of the more proximal (17p13.1) 17p change could
be TP53. Indeed, loss at 17p is the most common genetic
alteration thus far detected in ovarian cancer, with mutation
rates as high as 50% in advanced stage carcinomas [46].
However, we did not perform any further, detailed analysis
to see if TP53 or possibly other gene(s) were directly involved
in the losses detected in this series.
DNA microsatellite instability reﬂects an altered pattern
of short tandem repeat sequences (microsatellites) in divid-
ing cells and has been described in HNPCC as well as other
tumor types. Ovarian cancer, although most often sporadic,
can occur together with HNPCC as part of the Lynch
cancer family syndrome [47]. Several studies have suggested
an association between MSI and certain histological types
of ovarian carcinoma. However, in most of these studies,
diﬀerent kinds of microsatellite markers were used, and the
presence of MSI was declared based on the demonstration
of instability at only one locus [48–52]. In studies where the
NCI markers and criteria were used, Sood et al. [53]f o u n d
MSI-H in 12% of invasive carcinomas, whereas Gras et al.
[54] reported that MSI-H was limited to endometrioid and
clear cell carcinomas (12.5%). Liu et al. [55]a n dC a ie ta l .
[56] found that 20% of endometrioid carcinomas were MSI-
H. In our series of bilateral ovarian carcinomas, where 22 of
32 were serous papillary tumors, all cases but one (tumors 9a
and 9c; these tumors were serous papillary carcinomas and
MSI-L)wereMSS.Thisisinagreementwithpreviousstudies
ﬁnding that most of the MSI were scored in tumors of the
clear cell and endometrioid subtype of ovarian cancer.
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